Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PCLX-001 |
Synonyms | |
Therapy Description |
PCLX-001 inhibits the N-myristoyl-transferases NMT1 and NMT2, potentially resulting in inhibition of early B-cell receptor signaling and degradation of pERK, c-Myc, NFkappaB and CREB, which may lead to apoptosis and decreased tumor cell proliferation (Blood (2019) 134 (Supplement_1): 3362, Cancer Res 2020;80(16 Suppl):Abstract nr 5156). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PCLX-001 | PCLX 001|PCLX001 | PCLX-001 inhibits the N-myristoyl-transferases NMT1 and NMT2, potentially resulting in inhibition of early B-cell receptor signaling and degradation of pERK, c-Myc, NFkappaB and CREB, which may lead to apoptosis and decreased tumor cell proliferation (Blood (2019) 134 (Supplement_1): 3362, Cancer Res 2020;80(16 Suppl):Abstract nr 5156). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04836195 | Phase I | PCLX-001 | Phase I Trial of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma | Recruiting | CAN | 0 |